Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Lymphoma Research Foundation Announces New Scientific Advisory Board Members
  • USA - English


News provided by

Lymphoma Research Foundation

Jul 24, 2014, 15:00 ET

Share this article

Share toX

Share this article

Share toX

New York, NY (PRWEB) July 24, 2014 -- The Lymphoma Research Foundation (LRF) has announced the election of six experts in the field of lymphoma research to its prestigious Scientific Advisory Board (SAB). Comprised of the world’s leading lymphoma researchers and oncologists, the Scientific Advisory Board directs the LRF research portfolio, seeking out the most innovative and promising lymphoma research projects for support. The 45-member SAB reviews grant proposals and makes recommendations regarding research priorities and funding to the Foundation Board of Directors. The SAB also evaluates the progress of on-going research projects and guides the strategic direction of the Foundation’s research programs and consortia.

The six new members of the Foundation’s Scientific Advisory Board include:

Sven de Vos, MD, PhD is an Associate Professor of Medicine, Div. of Hematology/Oncology at the University of California Los Angeles’ David Geffen School of Medicine and the Director of the UCLA Lymphoma Program. He is a member of the Stem Cell Biology Program Area and the Chair of the Data Safety and Monitoring Board of the Jonsson Comprehensive Cancer Center. His research interests are in the development of new therapeutics for the treatment of lymphomas. He holds an MD and a doctorate in virology from the University of Tubingen, as well as a PhD in pathology from UCLA. After residencies in neurology at the University in Essen and in internal medicine at Cedars-Sinai Medical Center, he completed a hematology/oncology fellowship program at UCLA. He held research fellowships at the University in Freiburg and at Cedars-Sinai Medical Center/UCLA. He is a current member of LRF’s Mantle Cell Lymphoma (MCL) Consortium and a past LRF Postdoctoral Fellowship recipient.

Andrew Evens, DO, MSc is Director of Tufts Cancer Center, Chief of the Division of Hematology/Oncology, and Director of the Lymphoma Program at Tufts Medical Center. He is also a Professor at Tufts University School of Medicine. His clinical and research interests encompass both non-Hodgkin and Hodgkin lymphomas, including autologous stem cell transplantation. He maintains an active translational lymphoma laboratory studying transcription pathways, free radical-mediated biology, and the development of novel targeted agents for the treatment of lymphoma. Dr. Evens received his DO from the Chicago College of Osteopathic Medicine at Midwestern University before completing his residency at Lutheran General Hospital and a fellowship at Northwestern University. He currently co-chairs an annual Chicago Lymphoma Symposium and also chairs the Lymphoma Research Foundation’s New England Lymphoma Rounds program, as well as presents at several LRF professional and patient education programs. He was a faculty member for the inaugural LRF Clinical Research Mentoring Program in February 2014.

Eric Hsi, MD is the Section Head of Hematopathology and Medical Director of the automated hematology, flow cytometry, and immunohistochemistry laboratories in the Institute of Pathology and Laboratory Medicine at Cleveland Clinic. His research interests include diagnostic and biologic prognostic markers in hematologic malignancy, as well as development of new therapeutics. Dr. Hsi received his MD from the University of Michigan where he also completed his residency and fellowship. He is Chair of the Pathology Committee for the Alliance for Clinical Trials in Oncology, an Editorial Board Member on several journals including the American Journal of Clinical Pathology, and has served on LRF grant review committees.

Brian K. Link, MD is Professor of Internal Medicine – Hematology, Oncology, and Blood and Marrow Transplantation at the University of Iowa’s Carver College of Medicine. He directs the Translational Research Support Resource and the Lymphoma clinical services for the Holden Comprehensive Cancer Center. His research and clinical interests include indolent lymphomas, particularly follicular lymphoma. He is part of the University of Iowa/Mayo Clinic Lymphoma SPORE, where he co-directs the Lymphoma Molecular Epidemiology Resource and is clinical co-leader on a project investigating in situ immunization using nanoparticles. Dr. Link received his MD from the University of Iowa before completing his residency at Rush Presbyterian St. Luke’s Hospital in Chicago, and returning to Iowa for his hematology/oncology fellowship. He has previously served as a member of the speaking faculty for several LRF patient education programs.

Laurie H. Sehn, MD, MPH is a Clinical Associate Professor at the University of British Columbia and a Medical Oncologist at the BC Cancer Agency, where she is also a Clinical Investigator and Chair of the Lymphoma Tumor Group. Her research interests include the development of novel therapies for lymphoid cancers with particular interest in the biology and treatment of large cell lymphoma, the application of new imaging techniques such as PET scanning to lymphoma management, and innovative new approaches to treatment. She received her MD from McGill Medical School in Montreal, before completing a residency at Columbia Presbyterian Medical Center and a hematology-oncology fellowship at Brigham and Women’s Hospital and Dana Farber Cancer Institute. Dr. Sehn also has a MPH from Harvard School of Public Health. She is currently on the board of directors and Director of Research Fellowships for Lymphoma Foundation Canada and the Chair of the Scientific Advisory Board for the International Lymphoma Coalition.

Margaret Shipp, MD is the Chief of the Division of Hematologic Neoplasia at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. She is also the Director of the Lymphoma Program at the Dana Farber/ Harvard Cancer Center. Her research and clinical interests are primarily in aggressive B-cell non-Hodgkin lymphomas and Hodgkin lymphoma, particularly cellular and molecular features, tumor microenvironment and targeted therapies. Dr. Shipp received her MD from Washington University School of Medicine, St. Louis, where she also completed her residency. She subsequently completed a Medical Oncology fellowship at Dana-Farber Cancer Institute. Dr. Shipp has previously served on the Lymphoma Research Foundation’s MCL and diffuse large B-cell lymphoma grant review committees.

“The Lymphoma Research Foundation’s Scientific Advisory Board is comprised of the preeminent lymphoma specialists in the world and we are thrilled to have these six prominent individuals lend their expertise and talents to our Scientific Advisory Board,” said LRF Chief Executive Officer Elizabeth Thompson.

The new members’ five-year terms began July 1, 2014.

“Members of the Lymphoma Research Foundation’s Scientific Advisory Board are leaders in blood cancer research and lymphoma care; the expertise of the newly elected Scientific Advisory Board members will complement that of the SAB and enable us to make a meaningful difference in the field of lymphoma research,” said Dr. John P. Leonard, Chair of LRF’s Scientific Advisory Board, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology and Associate Dean for Clinical Research at Weill Cornell Medical College. “I look forward to working with the newest SAB members as we continue to make strides to eradicate lymphoma."

For more information about the Lymphoma Research Foundation’s research program, visit lymphoma.org/research.

About the Lymphoma Research Foundation
The Lymphoma Research Foundation (LRF) is the nation’s largest non-profit organization devoted to funding innovative research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives and patient services. To date, LRF has awarded more than $55 million in lymphoma-specific research.

For additional information on LRF’s research, education and services, please visit lymphoma.org.

Peggy Ann Torney, Lymphoma Research Foundation, http://lymphoma.org, +1 646-465-9109, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.